CureVac N.V.
CVAC
ISIN NL0015436031 / Valor 56537572
CureVac N.V.
UMushroom community rating:
About company
CureVac N.V. is a pioneering biopharmaceutical company that was officially founded in 2000 and is recognized as the world's first company to effectively utilize mRNA for medical applications. With over 1000 dedicated employees, CureVac is focused on leveraging its proprietary mRNA technology to develop personalized solutions for individuals with significant medical requirements. The company's groundbreaking discovery has revolutionized the potential for mRNA to treat diseases and create vaccines, positioning CureVac at the forefront of innovative medical research and development.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (16.10.2025):
In the fourth quarter of 2024, CureVac N.V. reported a robust financial performance, highlighting significant corporate transformation and enhanced financial discipline. The company maintains a strong cash position, ensuring financial stability through 2028, and achieved key milestones that underscore its strategic advancements.
Cash Position
CureVac ended 2024 with cash and cash equivalents totaling €481.7 million, reaffirming the company's expected cash runway into 2028.
Milestone Payments
The company invoiced a €10 million milestone payment following the initiation of Phase 1 of the combined Phase 1/2 study for its seasonal influenza/COVID-19 combination vaccine, which has been fully licensed to GSK.
Financial Discipline
Strategic restructuring and improved financial management have positioned CureVac for stronger future performance, supported by the recent validation of its intellectual property in Europe.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1133 M
Market cap (USD)
1,378,710
Daily traded volume (Shares)
3.22 / 3.04
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
